Free Tool
Ozempic Weight Loss Calculator
This calculator looks up the average weight change published for Ozempic (semaglutide) in SUSTAIN 1 and SUSTAIN FORTE. It reports what happened in a trial. It does not predict what will happen to you.
These figures come from trials in adults with type 2 diabetes, where weight loss is typically smaller. For the obesity-trial results of the same medication (semaglutide), see the Wegovy weight loss calculator.
The published result
In SUSTAIN 1, adults with type 2 diabetes taking Ozempic 1 mg had lost an average of 4.7 kg (10.4 lb) by week 30, from an average starting weight of 96.9 kg. This trial was in people with type 2 diabetes, where weight loss is typically smaller than in obesity trials of the same medication; see the Wegovy page for those.
This is the average result of a clinical trial, not a prediction of yours.
The dose is the maintenance dose each group was assigned to.
Other medications: Zepbound weight loss calculator · Wegovy weight loss calculator · Mounjaro weight loss calculator
What the trial found, by dose
| Placebo (n=129) | 0.5 mg once weekly (n=128) | 1 mg once weekly (n=130) | |
|---|---|---|---|
| Average starting weight | 89.1 kg | 89.8 kg | 96.9 kg |
| Average change at week 30 | −1.2 kg | −3.8 kg | −4.7 kg |
SUSTAIN 1 (ClinicalTrials.gov NCT02054897) enrolled 388 adults with type 2 diabetes inadequately controlled with diet and exercise and ran for 30 weeks. It compared Ozempic with placebo. How the figures were analysed: Intent-to-treat population (all randomized and exposed patients); ANCOVA adjusted for baseline value and country (label Table 3, footnotes a and b).
Source: OZEMPIC (semaglutide) injection prescribing information, Section 14.1, text following Table 3. U.S. National Library of Medicine, DailyMed. Label effective June 1, 2026; opened September 18, 2026. Read the prescribing information on DailyMed · SUSTAIN 1 on ClinicalTrials.gov
| 1 mg once weekly | 2 mg once weekly | |
|---|---|---|
| Average starting weight | 98.6 kg | 100.1 kg |
| Average change at week 40 | −5.6 kg | −6.4 kg |
SUSTAIN FORTE (ClinicalTrials.gov NCT03989232) enrolled 961 adults with type 2 diabetes treated with metformin, with or without a sulfonylurea and ran for 40 weeks. It compared Ozempic with semaglutide 1 mg once weekly (dose comparison; no placebo arm). How the figures were analysed: As printed in the label text following Table 7; the difference between arms in weight change was not statistically significant.
Source: OZEMPIC (semaglutide) injection prescribing information, Section 14.1, text following Table 7. U.S. National Library of Medicine, DailyMed. Label effective June 1, 2026; opened September 18, 2026. Read the prescribing information on DailyMed · SUSTAIN FORTE on ClinicalTrials.gov
How this calculator works
It looks up the average change in body weight, in kilograms, that the Ozempic prescribing information prints for the dose you choose, and shows it next to that group's average starting weight. It does not scale the figure to your weight, because the label reports kilograms for a group, not a percentage.
There is no week-by-week view. The prescribing information prints the result at the end of the trial only, so the calculator shows that result and does not estimate the weeks in between or anything after the trial ended.
Ozempic weight loss calculator questions
How much weight do people lose on Ozempic?
In SUSTAIN 1, the average weight loss at week 30 was 3.8 kg on 0.5 mg and 4.7 kg on 1 mg, against 1.2 kg on placebo. In SUSTAIN FORTE, the average weight loss at week 40 was 6.4 kg on 2 mg, against 5.6 kg on 1 mg once weekly. These are trial averages; individual results varied widely.
Is this a prediction of my weight loss on Ozempic?
No. It is a lookup of the average result published for a clinical trial. It cannot account for your health, your dose changes, your diet or your activity, and individual results in the trial varied widely. Talk to your prescriber about what to expect.
How long did the Ozempic trial last?
SUSTAIN 1 ran for 30 weeks. SUSTAIN FORTE ran for 40 weeks. No result past the final week is shown, because the trial ended there.
Who took part in SUSTAIN 1 and SUSTAIN FORTE?
SUSTAIN 1 enrolled 388 adults with type 2 diabetes inadequately controlled with diet and exercise. SUSTAIN FORTE enrolled 961 adults with type 2 diabetes treated with metformin, with or without a sulfonylurea.
Why are the Ozempic results in kilograms rather than percent?
Because that is how the Ozempic prescribing information reports body weight for these trials. The figure is shown as printed, next to the group's average starting weight, rather than converted into a percentage the label does not state or scaled to your own weight.
Why is the weight loss here smaller than on the Wegovy page?
The trials are different and cannot be compared directly. SUSTAIN 1 enrolled adults with type 2 diabetes inadequately controlled with diet and exercise and ran 30 weeks; SUSTAIN FORTE enrolled adults with type 2 diabetes treated with metformin, with or without a sulfonylurea and ran 40 weeks. STEP 1, shown on the Wegovy page, enrolled adults with obesity (BMI ≥30), or overweight (BMI 27 to 29.9) with at least one weight-related condition; type 2 diabetes excluded and ran 68 weeks.
Where do these numbers come from?
OZEMPIC (semaglutide) injection prescribing information, Section 14.1, text following Table 3. U.S. National Library of Medicine, DailyMed (label effective June 1, 2026; SUSTAIN 1, ClinicalTrials.gov NCT02054897) and OZEMPIC (semaglutide) injection prescribing information, Section 14.1, text following Table 7. U.S. National Library of Medicine, DailyMed (label effective June 1, 2026; SUSTAIN FORTE, ClinicalTrials.gov NCT03989232). Every figure on this page is copied from that document.
Can this calculator tell me what Ozempic dose to take?
No. It does not recommend, set or adjust a dose. Your dose and how quickly it is increased are decided by your prescriber, following the prescribing information.
By GLP AI / Editorial. The trial figures and result wording on this page were reviewed by Teresa Maze, RDN, on September 18, 2026. The review did not cover anything else on the page.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The information provided should not be used for diagnosing or treating a health condition. Always consult your healthcare provider before starting, stopping, or changing any medication or treatment plan. Individual results may vary.